OpportunityAnalyzer: Sepsis and Septic Shock-Opportunity Analysis and Forecasts to 2026
August 2017
318
About the Report
About the Report
OpportunityAnalyzer: Sepsis and Septic Shock-Opportunity Analysis and Forecasts to 2026
Summary
Sepsis is a complex disease, which not only involves a wide array of causative agents, but also results in different individual immune responses, causing various single or multiple organ dysfunction(s). Late 2016, the sepsis and septic shock market embraced new consensus definitions for sepsis and septic shock, which for the first time mandate an organ dysfunction underlying an infection to be classified as suffering from sepsis or septic shock. Past clinical development of drugs has been hampered by late stage failures due to recruitment of heterogeneous patient populations. Recent advances in clinical trial design, particularly the adoption of adaptive clinical trials, has awakened the hope of new pipeline products entering the sepsis and septic shock marketplace. However, physicians remain cautious, as reliable biomarkers to stratify these patients to these new pipeline drugs are not anticipated to launch during the forecast period.
Today, the sepsis and septic shock market is dominated by generic products, as the management of patients with sepsis and septic shock is mainly relying on antimicrobial therapy, fluid resuscitation, vasopressors, anticoagulants, steroids, and immunoglobulin therapy. The competition is high for these therapies, and the market is saturated with many suppliers of inexpensive generics. The sepsis and septic shock market is anticipated to experience the arrival of four new first-in-class pipeline drugs (BMS-936559, recAP, Traumakine, and CYT107) and three improved therapeutic options (selepressin, thrombomodulin, and cefiderocol), as well as two new hemoperfusion devices (Toraymyxin and CytoSorb). GlobalData expects the global sepsis and septic shock market-which, for the purposes of this report, comprises the seven major pharmaceutical markets (7MM; US, France, Germany, Italy, Spain, UK, Japan)-to expand during the next decade at an astonishing CAGR of 7.9%, reaching total sales ofUSD5.9 billion by 2026.
Scope
Overview of sepsis and septic shock, including epidemiology, etiology, pathophysiology, as well current routine sepsis and septic shock recommendations of all 7MM covered.
Top-line sepsis and septic shock market revenue from 2016-2026. Recent acquisitions, approvals and governmental recommendations are included in the forecast model.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, clinical trial design, and influence of new consensus definitions for the sepsis and septic shock market.
Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.
Analysis of the current and future market competition in the global sepsis and septic shock marketplace. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to-
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global sepsis and septic shock market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the sepsis and septic shock market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Products
Companies
AM-Pharma
Asahi Kasei Pharma Corp
Bristol-Myers Squibb
CytoSorbents
Faron
Ferring Holding
Pfizer
RevImmune
Shionogi
Spectral Diagnostics
Table of Contents
Table of Contents
1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Sepsis and Septic Shock: Executive Summary
2.1 Global Sepsis and Septic Shock Market to Experience Strong Growth on Launch of First-in-Class Pipeline Products
2.2 Developers Must Leverage Innovative R&D Strategies to Target Appropriate Patients and Achieve Sustained Commercial Success
2.3 A High Level of Unmet Need Persists in the Sepsis and Septic Shock Marketplace
2.4 Opportunities Remain for Current and Future Players to Develop Therapies Targeting Sepsis-Specific Pathophysiology
2.5 Immunomodulating Therapies Poised to Transform Sepsis and Septic Shock Market, but Missing Biomarkers Will Limit Their Utility
2.6 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification or Staging Systems
4.3 Symptoms
4.4 Prognosis
4.5 Quality of Life
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Forecast Assumptions and Methods
5.4.3 Diagnosed Incident Cases of Sepsis
5.4.4 Diagnosed Incident Cases of Septic Shock
5.4.5 Diagnosed Incident Cases of Sepsis/Septic Shock by Causative Agent
5.4.6 Organ Dysfunction among Diagnosed Incident Cases of Sepsis
5.4.7 Organ Dysfunction among Diagnosed Incident Cases of Septic Shock
5.4.8 Sepsis In-Hospital Mortality Cases
5.4.9 Septic Shock In-Hospital Mortality Cases
5.5 Epidemiological Forecast for Sepsis and Septic Shock ()
5.5.1 Diagnosed Incident Cases of Sepsis
5.5.2 Age-Specific Diagnosed Incident Cases of Sepsis
5.5.3 Sex-Specific Diagnosed Incident Cases of Sepsis
5.5.4 Diagnosed Incident Cases of Sepsis by Causative Agent
5.5.5 Organ Dysfunction among Diagnosed Incident Cases of Sepsis
5.5.6 Sepsis In-Hospital Mortality Cases
5.5.7 Age-Specific In-Hospital Mortality Cases of Sepsis
5.5.8 Diagnosed Incident Cases of Septic Shock
5.5.9 Age-Specific Diagnosed Incident Cases of Septic Shock
5.5.10 Sex-Specific Diagnosed Incident Cases of Septic Shock
5.5.11 Diagnosed Incident Cases of Septic Shock by Causative Agent
5.5.12 Organ Dysfunction among Diagnosed Incident Cases of Septic Shock
5.5.13 Septic Shock In-Hospital Mortality Cases
5.5.14 Age-Specific In-Hospital Mortality Cases of Septic Shock
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of Analysis
5.6.3 Strengths of Analysis
6 Current Treatment Options
6.1 Overview
6.2 Diagnosis and Treatment
6.2.1 Diagnosis
6.2.2 Treatment Guidelines
6.3 Clinical Practice
6.3.1 Overview
6.3.2 Surviving Sepsis Campaign Bundles
6.3.3 Country Differences
6.4 Infection Control-Antibiotics and other Anti-infectives
6.4.1 Overview
6.4.2 Timing of Antibiotic Therapy
6.4.3 Dosing of Antibiotic Therapy
6.4.4 Antibiotic Resistance
6.4.5 Other Therapies-Antivirals, Antifungals, and Antiparasitics
6.5 Supportive Treatment Options for Sepsis and Septic Shock
6.5.1 Overview
6.5.2 Fluid Resuscitation, Vasopressors, Dobutamine, and Blood Transfusion
6.5.3 Mechanical Ventilation and Hemodialysis
6.6 Other Therapeutic Approaches to Sepsis and Septic Shock
7 Unmet Needs Assessment and Opportunity Analysis
7.1 Overview
7.2 Improved Biomarkers to Guide Treatment Decisions and Support Drug Development
7.2.1 Unmet Need
7.2.2 Gap Analysis
7.2.3 Opportunity
7.3 Novel Therapeutic Interventions Targeting Sepsis Pathophysiology
7.3.1 Unmet Need
7.3.2 Gap Analysis
7.3.3 Opportunity
7.4 Enhancing Effectiveness of Currently Available Interventions to Help Improve Clinical Outcomes
7.4.1 Unmet Need
7.4.2 Gap Analysis
7.4.3 Opportunity
7.5 Streamlined Regulatory Framework to Stimulate Clinical Research and Drug Development
7.5.1 Unmet Need
7.5.2 Gap Analysis
7.5.3 Opportunity
7.6 More reliable animal models to facilitate effective screening of lead candidates
7.6.1 Unmet Need
7.6.2 Gap Analysis
7.6.3 Opportunity
7.7 Improved Awareness among Healthcare Workers and the Public
7.7.1 Unmet Need
7.7.2 Gap Analysis
7.7.3 Opportunity
8 Research and Development Strategies
8.1 Overview
8.1.1 New SEPSIS-3 Consensus Definition to Guide Future R&D Efforts
8.1.2 Immuno-stimulatory Drugs for Late-Step Intervention
8.1.3 Other Specific Development Strategies
8.1.4 Anti-inflammatory Drugs for Early Intervention (IFX-1, Toraymyxin)
8.2 Clinical Trial Design
8.2.1 Overview
8.2.2 Traditional Clinical Trial Design
8.2.3 Adaptive Clinical Trial Design
8.2.4 Participant Enrolment Criteria
8.2.5 Endpoints
9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
9.2.1 Selepressin
9.2.2 Thrombomodulin (ART-)
9.2.3 recAP
9.2.4 Traumakine (Recombinant Human IFN-?-1a)
9.2.5 BMS-
9.2.6 CYT
9.2.7 Cefiderocol
9.2.8 Toraymyxin (PMX-R) 0
9.2.9 CytoSorb
9.3 Other Innovative Early-Stage Approaches
9.3.1 IFX-1
9.3.2 LB8 (tranexamic acid)
9.3.3 ALT-8
9.3.4 Salvecin
9.3.5 Opdivo (nivolumab)
9.3.6 Adrecizumab
9.3.7 LGT-9
9.4 Other Drugs in Development
9.4.1 Cx-1
9.4.2 HU-003 0
9.4.3 Pooled Human Plasma 0
9.4.4 BMS- 0
9.4.5 Motrem
10 Pipeline Valuation Analysis
10.1 Clinical Benchmark of Key Pipeline Drugs
10.2 Commercial Benchmark of Key Pipeline Drugs
10.3 Competitive Assessment
10.4 Top-Line 10-Year Forecast
10.4.1 US
10.4.2 5EU
10.4.3 Japan
11 Appendix
11.1 Bibliography
11.2 Abbreviations
11.3 Methodology
11.4 Forecasting Methodology
11.4.1 Diagnosed Sepsis and Septic Shock Patients
11.4.2 Percent Drug-Treated Patients
11.4.3 Drugs Included in Each Therapeutic Class
11.4.4 Launch and Patent Expiry Dates
11.4.5 General Pricing Assumptions 0
11.4.6 Individual Drug Assumptions
11.4.7 Generic Erosion
11.4.8 Pricing of Pipeline Agents
11.5 Primary Research-KOLsInterviewed for this Report
11.6 Primary Research-Prescriber Survey
11.7 About the Authors
11.7.1 Analyst
11.7.2 Therapy Area Director
11.7.3 Epidemiologist
11.7.4 Managing Epidemiologists
11.7.5 Global Director of Therapy Analysis and Epidemiology
11.7.6 Global Head and EVP of Healthcare Operations and Strategy
11.8 About GlobalData
11.9 Contact Us
11.10 Disclaimer
List of Figure
1.2 List of Figures
Figure 1: Global Sales for Sepsis and Septic Shock by Country, 2016 and 2026
Figure 2: Competitive Assessment of Marketed and Pipeline Agents in Sepsis and Septic Shock, 2016-2026
Figure 3: Sepsis Definition and Diagnosis Criteria as Outlined in SEPSIS-2 and SEPSIS-3
Figure 4: Common Causes and Origins of Sepsis
Figure 5: Common Manifestations of Sepsis
Figure 6: The Pathogenesis of Sepsis and End-Stage Organ Damage
Figure 7: Current Understanding of Sepsis and Septic Shock Pathophysiology
Figure 8: Biomarkers in Bacterial Sepsis Diagnosis
Figure 9: Potential Target Pathways for Sepsis Treatment
Figure 10: 7MM, Age-Standardized Diagnosed Incidence of Sepsis (Cases per ,000 Population), Both Sexes, All Ages, 2016
Figure 11: 7MM, Age-Standardized Diagnosed Incidence of Septic Shock (Cases per ,000 Population), Both Sexes, All Ages, 2016
Figure 12: 7MM, Sources Used and Not Used, Diagnosed Incident Cases of Sepsis 54
Figure 13: 7MM, Sources Used and Not Used, Diagnosed Incident Cases of Sepsis/Septic Shock by Causative Agent 55
Figure 14: 7MM, Sources Used and Not Used, Organ Dysfunction among Sepsis Cases 56
Figure 15: 7MM, Sources Used and Not Used, In-Hospital Mortality Cases of Sepsis
Figure 16: 7MM, Sources Used and Not Used, Diagnosed Incident Cases of Septic Shock
Figure 17: 7MM, Sources Used and Not Used, Organ Dysfunction of Septic Shock Cases
Figure 18: 7MM, Sources Used, In-Hospital Mortality Cases of Septic Shock 60
Figure 19: 7MM, Age-Specific Diagnosed Incident Cases of Sepsis, Both Sexes, All Ages, 2016
Figure 20: 7MM, Sex-Specific Diagnosed Incident Cases of Sepsis, Both Sexes, All Ages, 2016
Figure 21: 7MM, Diagnosed Incident Cases of Sepsis by Causative Agent, Both Sexes, All Ages, 2016
Figure 22: 7MM, Organ Dysfunction among Diagnosed Incident Cases of Sepsis, Both Sexes, All Ages, 2016
Figure 23: 7MM, Age-Specific In-Hospital Mortality Cases of Sepsis, Both Sexes, All Ages, 2016
Figure 24: 7MM, Age-Specific Diagnosed Incident Cases of Septic Shock, Both Sexes, All Ages, 2016
Figure 25: 7MM, Sex-Specific Diagnosed Incident Cases of Septic Shock, Both Sexes, All Ages, 2016
Figure 26: 7MM, Diagnosed Incident Cases of Septic Shock by Causative Agent, Both Sexes, All Ages, 2016
Figure 27: 7MM, Organ Dysfunction among Diagnosed Incident Cases of Septic Shock, Both Sexes, All Ages, 2016
Figure 28: 7MM, Age-Specific In-Hospital Mortality Cases of Septic Shock, Both Sexes, All Ages, 2016
Figure 29: Current Treatment Options for Sepsis and Septic Shock, 2017
Figure 30: Disease Management Timeline for Sepsis and Septic Shock
Figure 31: Sepsis and Septic Shock SEPSIS-3 Diagnosis Algorithm
Figure 32: International Treatment Algorithm Overview for Sepsis, Severe Sepsis, and Septic Shock
Figure 33: Key Events Shaping Clinical Practice in Sepsis and Septic Shock
Figure 34: Unmet Need and Opportunity in Sepsis and Septic Shock, 2017
Figure 35: Current Treatment Options and Associated Biomarkers for Sepsis and Septic Shock, 2017 1
Figure 36: Sepsis and Septic Shock-Phase II?III Pipeline, 2017 1
Figure 37: Bullseye Diagram of Products in Clinical Development for Sepsis and Septic Shock, 2017 1
Figure 38: Competitive Assessment of Marketed and Pipeline Agents for Sepsis-Specific Treatment Options-Sepsis and Septic Shock, 2016-2026
Figure 39: Competitive Assessment of Marketed and Pipeline Agents for Supportive Care Treatment Options-Sepsis and Septic Shock, 2016-2026 2
Figure 40: Competitive Assessment of Marketed and Pipeline Agents for Infection Control Treatment Options-Sepsis and Septic Shock, 2016-2026 2
Figure 41: Top-Line Sales for Sepsis and Septic Shock by Country/Region, 2016 and 2026 2
Figure 42: Top-Line Sales for Sepsis and Septic Shock by Region, 2016?2026 2
Figure 43: Global Sales for Sepsis and Septic Shock by Drug Class, 2016 and 2026 2
Figure 44: Sales for Sepsis and Septic Shock by Drug Class in the US, 2016 and 2026 2
Figure 45: Sales for Sepsis and Septic Shock by Drug Class in the US, 2016 and 2026 2
Figure 46: Sales for Sepsis and Septic Shock by Drug Class in the 5EU, 2016 and 2026 255
Figure 47: Sales for Sepsis and Septic Shock by Drug Class in the 5EU, 2016 and 2026 256
Figure 48: Global Sales for Sepsis nd Septic Shock by Country in the 5EU, 2016 and 2026 257
Figure 49: Global Sales for Sepsis and Septic Shock by Country in the 5EU, 2016?2026
Figure 50: Sales for Sepsis and Septic Shock by Drug Class in Japan, 2016 and 2026 2
Figure 51: Sales for Sepsis and Septic Shock by Drug Class in Japan, 2016 and 2026 2
List of Table
1.1 List of Tables
Table 1: Sepsis and Septic Shock: Key Metrics in the Seven Major Pharmaceutical Markets
Table 2: Guidelines for Stratification of Patients with SIRS, Sepsis, Severe Sepsis, and Septic Shock
Table 3: SEPSIS-2 Diagnostic Criteria (SIRS, Sepsis, Severe Sepsis, and Septic Shock)
Table 4: SEPSIS-3 Diagnostic Criteria (qSOFA, SOFA, Sepsis, and Septic Shock)
Table 5: Summary of Pathophysiological Events Causing Sepsis and Septic Shock
Table 6: Mediators of the Pro-inflammatory and Anti-inflammatory Responses
Table 7: ICD-10-CM Diagnosis Codes for Sepsis
Table 8: Symptoms Associated with Sepsis and Septic Shock
Table 9: Risk Factors and Comorbidities for Sepsis and Septic Shock
Table 10: 7MM, Diagnosed Incident Cases of Sepsis, Both Sexes, All Ages, Selected Years 2016-2026
Table 11: 7MM, Sepsis In-Hospital Mortality Cases, Both Sexes, All Ages, Selected Years 2016-2026
Table 12: 7MM, Diagnosed Incident Cases of Septic Shock, Both Sexes, All Ages, Selected Years 2016-2026
Table 13: 7MM, Septic Shock In-Hospital Mortality Cases, Both Sexes, All Ages, Selected Years 2016-2026
Table 14: Key Differences in Diagnosis Criteria according to new SEPSIS-3
Table 15: Treatment Guidelines for Sepsis and Septic Shock, 2017
Table 16:SSC Guidelines Compared
Table 17: Treatment Bundles for Sepsis Patients
Table 18: Commonly Used Antibiotics in Sepsis and Septic Shock and Important Gaps in Coverage, 2017
Table 19: Pivotal Studies of Timing of Antibiotic Treatment in Sepsis and Septic Shock
Table 20: Other Supportive Therapies To Be Implemented When Clinically Relevant
Table 21: Evolution of the Standard of Care in Sepsis and Septic Shock, 2017
Table 22: Summary of Minor Supportive Measures, 2017
Table 23: Key Strategies Pursued by Current Sepsis and Septic Shock Drug Developers
Table 24: Common Sepsis Comorbidities Being Targeted by Drug Developers 1
Table 25: Biomarkers for Assessment of Immune Status 154
Table 26: Key Late-Stage Pipeline Agents for Sepsis and Septic Shock, 2017 1
Table 27: Comparison of Therapeutic Classes in Development for Sepsis and Septic Shock, 2016-2026 1
Table 28: Product Profile-Selepressin 1
Table 29: Reported SAEs of selepressin During Phase II Study 1
Table 30: Selepressin SWOT Analysis, 2017 1
Table 31: Product Profile-Thrombomodulin (ART-) 1
Table 32: Thrombomodulin Clinical Efficacy Outcomes from RCTs 1
Table 33: ART- Phase IIb Trial-Important Treatment-Emergent AEs and SAEs Monitored 1
Table 34: Thrombomodulin SWOT Analysis, 2017 1
Table 35: Product Profile-recAP 1
Table 36: Reported Efficacy of Bovine AP in Phase II Studies 1
Table 37: recAP SWOT Analysis, 2017 1
Table 38: Product Profile-Traumakine 1
Table 39: TraumaKine SWOT Analysis, 2017 1
Table 40: Product Profile-BMS-6559 200
Table 41: Most Frequently Reported AEs and SAEs of BMS-6559* 202
Table 42: BMS-6559 SWOT Analysis, 2017 20
Table 43: Product Profile-CYT 205
Table 44: Immunological Effects of CYT in Cancer and HIV Patients 206
Table 45: CYT SWOT Analysis, 2017 207
Table 46: Product Profile-Cefiderocol
Table 47: CefiderocolSWOT Analysis, 2017 2
Table 48: Product Profile-Toraymyxin 2
Table 49: EUPHAS Trial-Toraymyxin Physiological End Points by Treatment Group at Baseline and 72 Hours 2
Table 50: EUPHAS Trial-Change in SOFA Scores by Treatment Group After 72 hours 2
Table 51: EUPHAS Trial-Event-Free Days and Days Spent in Hospital by Treatment Group 2
Table 52: Toraymyxin SWOT Analysis, 2017 2
Table 53: Product Profile-CytoSorb 2
Table 54: CytoSorb SWOT Analysis, 2017 2
Table 55: Innovative Early-Stage Therapies for Sepsis and Septic Shock, 2017 2
Table 56: Hospital Indices-ALT-836 2
Table 57: Safety Profile-ALT-836 2
Table 58: Drugs in Development for Sepsis and Septic Shock, 2017 2
Table 59: Clinical Benchmark of Key Sepsis-Specific Treatment Options-Sepsis and Septic Shock 2
Table 60: Clinical Benchmark of Key Supportive Care Treatment Options-Sepsis and Septic Shock 2
Table 61: Clinical Benchmark of Key Infection Control Treatment Options-Sepsis and Septic Shock 2
Table 62: Commercial Benchmark of Key Sepsis-Specific Treatment Options-Sepsis and Septic Shock 2
Table 63: Commercial Benchmark of Key Supportive Care Treatment Options-Sepsis and Septic Shock 2
Table 64: Commercial Benchmark of Key Infection Control Treatment Options-Sepsis and Septic Shock
Table 65: Top-Line Sales Forecast (USD M) for Sepsis and Septic Shock, 2016-2026 2
Table 66: Key Events Impacting Sales for Sepsis and Septic Shock, 2016-2026 2
Table 67: Sepsis and Septic Shock Market-Global Drivers and Barriers, 2016?2026
Table 68: Sales Forecasts (USD M) for Sepsis and Septic Shock in the US, 2016-2026 2
Table 69: Sales Forecast (USD M) for Sepsis and Septic Shock in the 5EU, 2016-2026 254
Table 70: Sales Forecasts (USD M) for Sepsis and Septic Shock in Japan, 2016-2026
Table 71: Key Projected Launch Dates for Sepsis and Septic Shock 2
Table 72: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.